Meanwhile, Apricus Biosciences is planning to file a
New Drug Submission in Canada for the company’s topical treatment for
onychomycosis, MycoVa. The Apricus stock is trading 7 percent higher in
pre-market trade.

Pharmaceutical company Exelixis, Inc.(NASDAQ:EXEL) has
said that trials have shown that even small doses of 40 milligrams of its
cabozantinib drug have similar effects as large doses in reducing metastatic
bone and soft tissue disease. The preliminary data of the Phase II trials were
released over the weekend. The pharma company’s stock has risen 4 percent in
early trade.

Positive cancer trial results push Ariad up

Another pharma company, Ariad Pharmaceuticals,
Inc.(NASDAQ:ARIA) has said that the initial clinical results for AP26113, used
for treating a kind of lung cancer are positive. The stock has risen 4 percent
in the pre-market session. It has already risen 98 percent during the year.

Macy’s seasonal hiring to be 2.5 percent higher

Macy’s Inc plans to appoint 80,000 seasonal
associates for its Macy’s and Bloomingdale’s stores. The number is 2.5 percent
higher than last year’s figures of 78,000. The seasonal associates work in
sales, store operations and also call centers, staff distribution and
fulfillment centers for online purchases where they have telephonic interactions
with customers.